Synapse - A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma

A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma Meeting Abstract

Authors:	Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Chen, R. W.; Constine, L. S.; Courtien, A.; Dandapani, S.; Drullinsky, P.; Friedberg, J. W.; Gerecitano, J.; Hamilton, A.; Hamlin, P. A.; Hoppe, R. T.; Horwitz, S. M.; Matasar, M. J.; Miller, S. T.; Moskowitz, A. J.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Schoder, H.; Straus, D. J.; Yang, J. C.; Younes, A.; Zelenetz, A. D.; Zhang, Z. G.; Yahalom, J.; Moskowitz, C. H.
Abstract Title:	A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
Meeting Title:	59th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	130
Issue:	Suppl. 1
Meeting Dates:	2017 Dec 9-12
Meeting Location:	Atlanta, GA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2017-12-07
Language:	English
ACCESSION:	WOS:000432419401381
PROVIDER:	wos
DOI:	10.1182/blood.V130.Suppl_1.734.734
Notes:	Meeting Abstract: 734 -- Source: Wos